|1.||Tousson, Ehab: 2 articles (03/2012 - 09/2011)|
|2.||El-Moghazy, Mostafa: 2 articles (03/2012 - 09/2011)|
|3.||Qingzuo, L: 1 article (12/2014)|
|4.||Jitao, W: 1 article (12/2014)|
|5.||Zhenli, G: 1 article (12/2014)|
|6.||Jianming, W: 1 article (12/2014)|
|7.||Li, C: 1 article (12/2014)|
|8.||Jinchen, H: 1 article (12/2014)|
|9.||Lei, S: 1 article (12/2014)|
|10.||Ferry, Arnaud: 1 article (09/2014)|
07/01/1985 - "The rate of T transformation into 5 alpha-dehydrotesosterone was higher but in patients with the idiopathic form of hirsutism whereas the level of 5 alpha-dehydrotestosterone was significantly decreased in all the patients. "
07/01/1985 - "A study was made of the endogenous testosterone (T) level in the blood plasma, the rate of T decomposition and the level of 5 alpha-dehydrotestosterone in the pubic skin of women with hirsutism of different genesis. "
11/01/1986 - "The authors revealed reverse correlation of the concentration of total testosterone, its free fraction and the number of common sites of the binding of dehydrotestosterone with receptor proteins as well as the frequency of detection of androgen free receptors in the pubic skin cytosol of patients with a various degree of hirsutism."
09/01/1988 - "The content of total testosterone (T), dehydrotestosterone (DHT), androstenedione (A), estradiol (E2), luteotropin (LH) and follicle-stimulating hormone (FSH) was studied in patients with ovarian and idiopathic hirsutism by a radioimmunoassay. "
|3.||Prostatic Neoplasms (Prostate Cancer)
09/01/2009 - "Further studies in the androgen-responsive LNCaP human prostate cancer cell line showed that BPEx inhibited dose-dependently testosterone-induced cell growth, while the inhibitory activities of BPEx did not appear against dehydrotestosterone-induced cell growth. "
01/01/1996 - "For men, interest has centred on the use of 5 alpha-reductase inhibitors to block the prostatic conversion of testosterone to dehydrotestosterone and potentially inhibit the development of prostate cancer. "
12/01/1998 - "The objective was to determine differences in cell kinetic parameters and volume growth of tumors growing with alpha-dehydrotestosterone (alphaDHT) and without alphaDHT. "
08/01/2009 - "Primary tumor cultures and PCa cell lines were treated with bicalutamide (0.1-10 microM) in the presence of dehydrotestosterone (10(-12) M) for 4 days. "
12/01/2004 - "A high concentration of androgens might play a role in tumor aggressiveness of LNCaP cells, given that enhanced mRNA expressions of integrin alphaV and vascular endothelial growth factor was induced by dehydrotestosterone administration in vitro. "
01/01/1998 - "The direct effector factors-protein growth factors, the regulatory factors: activators (5-alpha-reductase, dehydrotestosterone, prostatic specific antigen) and inhibitors (tumor suppressors and metastatic suppressors, insulin-like growth factor-binding protein type 3) were analyzed and systematized. "
|5.||Body Weight (Weight, Body)
05/01/2012 - "Three experimental groups include animals that receive one, two and three intramuscular injections of 5 mg/kg body weight boldenone, and dissected after 3, 6, and 9 weeks, respectively, and the interval of each dose of boldenone was 3 weeks. "
03/01/2012 - "Three experimental groups include animals that receive 1, 2, and 3 intramuscular injections of 5 mg/kg body weight boldenone, and dissected after 3, 6, and 9 weeks, respectively. "
09/01/2011 - "The experimental groups include animals that receive one, two and three intramuscular injections of 5 mg/kg body weight boldenone, respectively. "
|2.||Follicle Stimulating Hormone (Follitropin)
|3.||Androstenedione (4 Androstene 3,17 dione)
|5.||Luteinizing Hormone (Lutropin)
|8.||5-alpha Reductase Inhibitors
|9.||Cholestenone 5 alpha-Reductase (5 alpha-Reductase)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)